Related Experiment Video
Updated: May 27, 2026
07:15
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway
Rong Zheng1, Yueyi Deng, Yiping Chen
1Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Phytotherapy Research : PTR
|November 17, 2011
Summary
Astragalus membranaceus, a traditional Chinese medicine, may treat membranous nephropathy (MN) by protecting kidney podocytes. Its active compound, astragaloside IV (AS-IV), reduces podocyte injury and regulates key signaling pathways involved in MN.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Membranous nephropathy (MN) is a leading cause of adult nephrotic syndrome, characterized by podocyte injury.
- Astragalus membranaceus is traditionally used in China to treat MN, with documented benefits for proteinuria.
- The precise mechanism by which Astragalus membranaceus alleviates MN remains unclear.
Purpose of the Study:
- To investigate the therapeutic mechanism of Astragalus membranaceus in a podocyte injury model relevant to MN.
- To elucidate how astragaloside IV (AS-IV), a key component, impacts podocyte damage and signaling pathways.
Main Methods:
- Utilized a complement membranous attack complex-induced podocyte injury model.
- Assessed lactate dehydrogenase (LDH) release as an indicator of cell damage.
- Evaluated podocyte morphology, cytoskeleton integrity, and the phosphorylation status of JNK and ERK1/2.
Main Results:
- Complement attack complex increased LDH release from podocytes; AS-IV inhibited this release dose-dependently.
- AS-IV treatment restored podocyte morphology and reversed cytoskeleton damage.
- AS-IV reduced the phosphorylation of JNK and ERK1/2 pathways induced by complement attack.
Conclusions:
- Astragalus membranaceus may treat MN by protecting podocytes from injury.
- The mechanism involves maintaining podocyte cytoskeleton integrity and modulating mitogen-activated protein kinase (MAPK) signaling.
- AS-IV is a key active compound in Astragalus membranaceus responsible for these protective effects.
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:42Microtubule Associated Proteins (MAPs)
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...